From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

Op-ed: By investing in a peer workforce, policymakers can help Latinx communities overcome barriers to accessing quality HIV ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

People at risk for contracting HIV from sex can reduce their risk of infection by up to 99% when they take pre-exposure ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...